Dr. Barentsz' research focuses on the following aims: 

1. Implementation of PSA + prostate-MRI for early detection of prostate cancer. Use of artificial intelligence for quality control of prostate MR-image-acquisition and -interpretation.

2. Providing international virtual interactive, hands-on education to help radiologists become prostate-MRI experts. To achieve this, he is also working to implement quality control through accreditation and certification, and he is establishing an (inter)national prostate-MRI excellence network. 

3. Enable global marketing-approval of ferumoxtran-10 as MR-contrast agent, and implement nano-MRI as guidance for focal radiotherapy to treat nodal micro-metastases.

4. Establishing an International Excellence Center for Prostate-MRI in Diagnosis and Treatment.

He is known for his determination and sometimes stubborn nature in making decisions, but he is also open to good ideas. For example, when he suggested using MRI to detect clinically significant prostate cancer, urologists initially opposed the idea. However, he persevered and has now been honored with the 2020 EAU Innovators in Urology Award by European urologists. He also holds the position of Imaging Editor on the Executive Editorial Board of European Urology, where he works to promote imaging tools that benefit patients. In his pursuit of these goals, he can sometimes become impatient due to his strong commitment and passion. He occasionally forgets that changes in medical care may take time. He is frequently sought after as a member of the Prostate Cancer Patient Society's Advisory Board and willingly assists many patients, even outside normal working hours, providing them with imaging support.

In addition, he actively contributes to research in the field of prostate cancer imaging and therapy. His expertise and dedication have made him a respected figure in the medical community. He is known for his willingness to go above and beyond helping patients, even providing support outside of regular working hours.

He has authored over 350 papers, with seven published within the past two years and having a high-impact factor (> 20). His h-factor is 109 with more than 40,000 citations (Google Schoolar). Consequently, he has inspired numerous young researchers to produce exceptional articles.

Furthermore, he frequently presents his work at national and international conferences, contributing to the dissemination of knowledge in the field. He actively participates in collaborations with other institutions and clinicians, aiming to advance the effectiveness and accessibility of prostate cancer diagnosis and treatment.

Moreover, his dedication to education is evident in his role as a mentor and supervisor for medical students, residents, and fellows interested in prostate cancer imaging and therapy.

Patients and colleagues alike appreciate his approachable and compassionate nature, as he takes the time to listen attentively to their concerns, and ensure that they are well-informed and comfortable with their treatment plans. He consistently demonstrates a commitment to individualized care, tailoring approaches to the unique needs of each patient.

Overall, his expertise, passion for research, and patient-centred approach have made him a highly regarded specialist in prostate cancer imaging and therapy, shaping the standard of care in this important area of medicine.